Search

Your search keyword '"Schetelig, Johannes"' showing total 523 results

Search Constraints

Start Over You searched for: Author "Schetelig, Johannes" Remove constraint Author: "Schetelig, Johannes" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
523 results on '"Schetelig, Johannes"'

Search Results

1. How risky is a second allogeneic stem cell transplantation?

2. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

3. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

4. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

5. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

7. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

8. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

9. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

10. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

13. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

14. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

15. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

16. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

17. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

18. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy

20. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML

21. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

22. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation

24. Following Transplantation for Acute Myelogenous Leukemia, Donor KIR Cen B02 Better Protects against Relapse than KIR Cen B01.

25. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

30. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

31. Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation

33. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

34. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

35. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

36. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

37. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

39. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

40. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

41. Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS

42. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

43. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

44. Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

45. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight.

47. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

48. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

49. The clinical mutatome of core binding factor leukemia

Catalog

Books, media, physical & digital resources